Concepedia

Michael L. Meyers

ML

Statistics

Publications

32

Citations

2.5K

H-Index

23

Active since

1986

Affiliations

Synta Pharmaceuticals (United States)(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Sarah Cannon

Roswell Park Comprehensive Cancer Center

Michael L. Meyers is an author at Synta Pharmaceuticals (United States) specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

1986–2023

32

Publications

32

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

Paul B. Chapman, Lawrence H. Einhorn, Michael L. Meyers et al. · Journal of Clinical Oncology · 1999 · 758 citations

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Nature · 2023 · 420 citations · Full text

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21

Govindaswami Ragupathi, Michael L. Meyers, Sucharita Adluri et al. · International Journal of Cancer · 2000 · 124 citations

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Matthew D. Hellmann, Pasi A. Jänne, Mateusz Opyrchal et al. · Clinical Cancer Research · 2020 · 115 citations · Full text

Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

Jonathan J. Lewis, Sylvia Janetzki, Susanne G. Schaed et al. · International Journal of Cancer · 2000 · 105 citations · Full text

1–5 of 32